Digestive Diseases and Sciences

, Volume 40, Issue 10, pp 2098–2106 | Cite as

Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis

  • Albert J. Czaja
  • Herschel A. Carpenter
  • Paula J. Santrach
  • S. Breanndan Moore
Liver: Infectious, Inflammatory, and Metabolic Disorders

Abstract

Immune mechanisms have been implicated in chronic viral hepatitis, and these may be influenced by genetic factors. To determine if disease severity in chronic viral hepatitis is associated with the human leukocyte antigens DR3 and/or DR4, 109 patients were evaluated prospectively. The frequencies of DR3 and DR4 in these patients were compared to those in 80 normal subjects. Patients with DR3 and/or DR4 had the same occurrence of severe disease as patients with other DR antigens (21% versus 30%,P=0.3). Patients with DR3, however, had higher serum gamma globulin and immunoglobulin G levels than patients with DR4 and a greater frequency of severe disease (36% vs 12%,P=0.046). Patients with DR4 had concurrent immunologic diseases more commonly than patients with DR3 (44% vs 9%,P=0.005) and patients with other DR antigens (44% vs 9%,P=0.0002). Patients with DR4 but not DR3 had severe disease less frequently than other patients (9% vs 31%,P=0.02). The frequencies of DR3 in patients with severe disease (37% vs 18%,P=0.06) and DR4 in patients without severe disease (44% vs 30%,P=0.07) were different than those in normal subjects but not to a statistically significant level. We conclude that patients with DR3 and DR4 have different clinical and laboratory findings and disease severity. Patients with DR4 have milder disease than patients with other DR antigens. Disease severity, however, is not closely associated with DR3 or DR4.

Key Words

Leucocyte antigens viral hepatitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Williams RM, Martin S, Falchuk KR, Trey C, Dubey DP, Cannady WG, Fitzpatrick D, Noreen H, Dupont B, Yunis EJ: Increased frequency of HLA-DRW4 in chronic active hepatitis. Vox Sang 35:366–369, 1978Google Scholar
  2. 2.
    Mackay IR, Tait BD: HLA associations with autoimmune-type chronic active hepatitis: Identification of B8-DRw3 haplotype by family studies. Gastroenterology 79:95–98, 1980Google Scholar
  3. 3.
    Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R: Susceptibility of autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13:701–706, 1991Google Scholar
  4. 4.
    Opelz G, Vogten AJM, Summerskill WHJ, Schalm SW, Terasaki PI: HLA determinants in chronic active liver disease: Possible relation of HLA-Dw3 to prognosis. Tissue Antigens 9:36–40, 1977Google Scholar
  5. 5.
    Czaja AJ, Rakela J, Hay JE, Moore SB: Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroidtreated severe autoimmune chronic active hepatitis. Gastroenterology 98:1587–1593, 1990Google Scholar
  6. 6.
    Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH: Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 15:215–221, 1992Google Scholar
  7. 7.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502–1507, 1993Google Scholar
  8. 8.
    Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, Johnson PJ, Eddleston ALWF, Mowat AP, Williams R: Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19:609–615, 1994Google Scholar
  9. 9.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 18:816–822, 1993Google Scholar
  10. 10.
    Hood L, Steinmetz M, Malissen B: Genes of the major histocompatibility complex of the mouse. Annu Rev Immunol 1:529–568, 1983Google Scholar
  11. 11.
    Magrin S, Craxi A, Fiorentino G, Fabiano C, Provenzano G, Pinzello GB, Palazzo U, Almasio P, Pagliaro L: Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol 13:56–60, 1991Google Scholar
  12. 12.
    Magrin S, Craxi A, Fabiano C, Fiorentino G, Almasio P, Palazzo U, Pinzello G, Provenzano G, Pagliaro L, Choo Q-L, Kuo G, Polito A, Han J, Houghton M: Hepatitis C virus replication in “autoimmune” chronic hepatitis. J Hepatol 13:364–367, 1991Google Scholar
  13. 13.
    Cassani F, Muratori L, Manotti P, Lenzi M, Fusconi M, Ballardini G, selleri L, Volta U, Zauli D, Miniero R, Bianchi FB: Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: A reappraisal at the light of hepatitis C virus infection. Gut 33:1260–1263, 1992Google Scholar
  14. 14.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA: Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 18:342–352, 1993Google Scholar
  15. 15.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 108:157–164, 1995Google Scholar
  16. 16.
    Pawlotsky J-M, Yahia MB, Andre C, Voisin M-C, Intrator L, Roudot-Thoraval F, Deforges L, Duvoux C, Zafrani E-S, Duval J, Dhumeaux D: Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 19:841–848, 1994Google Scholar
  17. 17.
    Tran A, Quaranta J-F, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul J-L, Hebuterne X, Rampal P: High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18:253–257, 1993Google Scholar
  18. 18.
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Willson R: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328:465–470, 1993Google Scholar
  19. 19.
    Lisker-Melman M, Webb D, Di Bisceglie AM, Kassianides C, Martin P, Rustgi V, Waggoner JG, Park Y, Hoffnagle JH: Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon. Ann Intern Med 111:479:483, 1989Google Scholar
  20. 20.
    Baker AL, Kaplan MM, Benz WC, Sidel JS, Wolfe HJ: Polyarteritis associated with Australia antigen-positive hepatitis. Gastroenterology 62:105–110, 1972Google Scholar
  21. 21.
    Carson CW, Conn DL, Czaja AJ, Wright TL, Brecher ME: Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 20:304–309, 1993Google Scholar
  22. 22.
    Haddad J, Deny P, Munz-Gotheil C, Ambrosini J-C, Trinchet J-C, Pateron D, Mal F, Callard P, Beaugrand M: Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 339:321–323, 1992Google Scholar
  23. 23.
    Lunel F, Musset L, Cacoub P, Franguel L, Cresta P, Perrin M, Grippon P, Hoang C, Piette JC, Huraux J-M, Opolon P: Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 106:1291–1300, 1994Google Scholar
  24. 24.
    Burman P, Totterman TH, Oberg K, Karlsson FA: Thyroid autoimmunity in patients on long term therapy with leukocytederived interferon. J Clin Endocrinol Metab 63:1086–1090, 1986Google Scholar
  25. 25.
    Mayet W-J, Hess G, Gerken G, Rossol S, Voth R, Manns M, Meyer zum Buschenfelde K-H: Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10:24–28, 1989Google Scholar
  26. 26.
    Weber P, Weidmann K-H, Klein R, Walter E, Blum HE, Berg PA: Induction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferon. J Hepatol 20:321–328, 1994Google Scholar
  27. 27.
    Thomas HC, Montano L, Goodall A, de Koning R, Oladapo J, Wiedman KH: Immunological mechanisms in chronic hepatitis B virus infection. Hepatology 2:116S-121S, 1982Google Scholar
  28. 28.
    Gonzalez-Peralta RP, Davis GL, Lau JYN: Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 21:255–259, 1994Google Scholar
  29. 29.
    Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF: Autoimmune features as determinants of prognosis in steroidtreated chronic active hepatitis of uncertain etiology. Gastroenterology 85:713–717, 1983Google Scholar
  30. 30.
    Czaja AJ, Carpenter HA: Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824–1832, 1993Google Scholar
  31. 31.
    Geall MG, Schoenfield LJ, Summerskill WHJ: Classification and treatment of chronic active liver disease. Gastroenterology 63:458–465, 1972Google Scholar
  32. 32.
    Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ: Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63:820–833, 1972Google Scholar
  33. 33.
    Czaja AJ, Wolf AM, Baggenstoss AH: Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: Correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 80:687–692, 1981Google Scholar
  34. 34.
    Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ: Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 3:183–198, 1972Google Scholar
  35. 35.
    Schalm SW, Korman MG, Summerskill WHJ, Czaja AJ, Baggenstoss AH: Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 22:973–980, 1977Google Scholar
  36. 36.
    Czaja AJ, Manns MP, Homburger HA: Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103:1290–1295, 1992Google Scholar
  37. 37.
    Czaja AJ, Nishioka M, Morshed SA, Hachiya T: Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107:200–207, 1994Google Scholar
  38. 38.
    Bidwell JL, Bidwell EA, Savage DA, Middleton D, Klouda PT, Bradley BA: A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10. Transplantation 45:640–646, 1988Google Scholar
  39. 39.
    Noreen HJ, Davidson ML, McCullough J, Bach FH, Segall M: HLA class II typing by restriction fragment length polymorphism (RFLP) in unrelated bone marow transplant patients. Transplant Proc 21:2968–2970, 1989Google Scholar
  40. 40.
    Mytilineos J, Scherer S, Oplez G: Comparison of RFLP-DR beta and serological HLA-DR typing in 1500 individuals. Transplantation 50:870–873, 1990Google Scholar
  41. 41.
    Bodmer JG, Marsh SGE, Albert ED, Bodmer WF, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasazuki T, Schreuder GMT, Strominger JL, Svejgaard A, Terasaki PI: Nomenclature for factors of the HLA system, 1991. Hum Immunol 34:4–18, 1992Google Scholar
  42. 42.
    Zetterquist H, Olerup O: Identification of the HLA-DRB1*04,-DRB1*07, and-DRB1*09 alleles by PCR amplication with sequence-specific primers (PCR-SSP) in 2 hours. Hum Immunol 34:64–74, 1992Google Scholar
  43. 43.
    Louzir H, Ternynck T, Gorgi Y, Tahar S, Ayed K, Avrameas S: Autoantibodies and circulating immune complexes in sera from patients with hepatitis B virus-related chronic liver disease. Clin Immunol Immunopathol 62:160–167, 1992Google Scholar
  44. 44.
    Eddleston ALWF, Mondelli M, Mieli-Vergani G, Williams R: Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. Hepatology 2:122S-127S, 1982Google Scholar
  45. 45.
    Eddleston ALWF, Williams R: Inadequate antibody response to HBs antigen or suppressor T-cell defect in the development of active chronic hepatitis. Lancet 2:1543–1548, 1974Google Scholar
  46. 46.
    Nouri-Aria KJ, Hegarty JE, Alexander GJM, Eddleston ALWF, Williams R: Effect of corticosteroids on suppressorcell activity in “autoimmune” and viral chronic active hepatitis. N Engl J Med 307:1301–1304, 1982Google Scholar
  47. 47.
    Hino K, Okuda M, Konishi T, Yamashita A, Kayano K, Kubota M, Yasunaga M, Fukumoto Y, Okita K: Analysis of lymphoid follicles in liver of patients with chronic hepatitis C. Liver 12:387–391, 1992Google Scholar
  48. 48.
    Mosnier J-F, Degott C, Marcellin P, Henin D, Erlinger S, Benhamou J-P: The intraportal lymphoid nodule and its environment in chronic active hepatitis C: An immunohistochemical study. Hepatology 17:366–371, 1993Google Scholar
  49. 49.
    Mosnier J-F, Scoazec J-Y, Marcellin P, Degott C, Benhamou J-P, Feldmann G: Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. Gastroenterology 107:1457–1468, 1994Google Scholar
  50. 50.
    Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Brunetto MR, Bonino F, Abrignani S: Compartmentalization of T lymphocytes to the site of disease: Intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis. C. J Exp Med 178:17–25, 1993Google Scholar
  51. 51.
    Fong T-L, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG: Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 107:196–199, 1994Google Scholar
  52. 52.
    Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L: Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 40:33–40, 1995Google Scholar
  53. 53.
    Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088–1094, 1994Google Scholar
  54. 54.
    Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchez-Pescador R, Detmer J, Wilber JC, Pagliaro L: Hepatitis C viremia in chronic liver disease: Relationship to interferon-alpha or corticosteroid therapy. Hepatology 19:273–279, 1994Google Scholar
  55. 55.
    Yosioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T: Deterction of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relationship to genotypes of hepatitis C virus. Hepatology 16:293–299, 1992Google Scholar
  56. 56.
    Takada N, Takase S, Enomoto N, Takada A, Date T: Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 14:35–40, 1992Google Scholar
  57. 57.
    Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap P-L, Sherlock S, McIntyre N, Simmonds P: Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease. Hepatology 19:13–18, 1994Google Scholar
  58. 58.
    Okada S-I, Akahane Y, Suzuki H, Okamoto H, Mishiro S: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619–624, 1992Google Scholar
  59. 59.
    Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T: Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20:1121–1130, 1994Google Scholar
  60. 60.
    Czaja AJ, Taswell HF, Rakela J, Schimek C: Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. J Hepatol 14:88–93, 1992Google Scholar
  61. 61.
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PYH, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ: The natural history of communityacquired hepatitis C in the United States. N Engl J Med 327:1899–1905, 1992Google Scholar
  62. 62.
    Lok ASF, Cheung R, Chan R, Liu V: Hepatitis C viremia in patients with hepatitis C virus infection. Hepatology 15:1007–1012, 1992Google Scholar
  63. 63.
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435, 1981Google Scholar
  64. 64.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Albert J. Czaja
    • 1
    • 2
  • Herschel A. Carpenter
    • 1
    • 2
  • Paula J. Santrach
    • 1
    • 2
  • S. Breanndan Moore
    • 1
    • 2
  1. 1.Division of Gastroenterology and Internal MedicineMayo Clinic and Mayo FoundationRochester
  2. 2.Department of Laboratory Medicine and PathologyMayo Clinic and Mayo FoundationRochester

Personalised recommendations